Leverage has risen sharply, with total debt of $243.3M and a debt-to-equity ratio of 0.42 at 2026Q3 compared with 0.04 a year earlier, while the current ratio of 14.46 looks strong but must be weighed against quarterly operating outflows of roughly $90M to $125M.
Viridian Therapeutics, Inc. (VRDN) balance sheet — 14-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 1.01B | 894.23M | 738.46M | 486.48M | 424.55M | 200.16M | 129.61M | 29.74M | 65.37M | 51.87M | 4.26M | 11.73M | 6.79M | 2.05M | 1.66M |
| Cash & Short-Term Investments | 955.21M | 874.65M | 717.58M | 477.37M | 424.55M | 196.97M | 127.64M | 26.84M | 62.48M | 47.44M | 3.34M | 10.83M | 5.12M | 209.35K | 112.53K |
| Cash Only | 172.86M | 212.38M | 99.59M | 102.83M | 155.58M | 42.3M | 45.9M | 24.85M | 32.61M | 47.44M | 3.34M | 10.83M | 5.12M | 209.35K | 112.53K |
| Short-Term Investments | 782.35M | 662.27M | 617.99M | 374.54M | 268.97M | 154.67M | 81.74M | 2M | 29.88M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 29.78M | 0 | 0 | 102K | 102K | 451K | 0 | 108K | 24K | 1.46M | 524K | 394K | 1.09M | 994.01K | 1.2M |
| Days Sales Outstanding | 363.43 | - | - | 118.57 | 21.01 | 55.56 | - | 8.84 | 1.04 | 132.76 | 57.31 | 56.66 | 91.93 | 84.05 | 99.04 |
| Inventory | 85K | 0 | 0 | 0 | -6.62M | 0 | 0 | 0 | 0 | 0 | 64K | 187K | 179K | 356.64K | 169.54K |
| Days Inventory Outstanding | 4.2 | - | - | - | - | - | - | - | - | - | 9.17 | 27.61 | 20.15 | 52.09 | 20.34 |
| Other Current Assets | 28.06M | 19.58M | 20.88M | 9.01M | 6.52M | 100K | 0 | -108K | 2.87M | 2.97M | 170K | 321K | 0 | 50K | 56.21K |
| Total Non-Current Assets | 15.54M | 5.18M | 3.94M | 3.95M | 10.54M | 3.55M | 1.64M | 523K | 777K | 613K | 883K | 1.17M | 1.3M | 1.62M | 1.12M |
| Property, Plant & Equipment | 5.62M | 3.65M | 3.44M | 3.34M | 2.94M | 2.06M | 787K | 523K | 727K | 563K | 625K | 1.15M | 1.21M | 928.03K | 1.07M |
| Fixed Asset Turnover | 6.01x | 19.42x | 0.09x | 0.09x | 0.60x | 1.44x | 1.33x | 8.53x | 11.54x | 7.11x | 5.34x | 2.20x | 3.56x | 4.65x | 4.11x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 9.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 131K | 1.54M | 501K | 604K | 7.61M | 1.49M | 857K | 0 | 50K | 50K | 258K | 15K | 90K | 690.05K | 45.58K |
| Total Assets | 1.03B | 899.42M | 742.4M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 4.26M | 12.9M | 8.09M | 3.67M | 2.78M |
| Asset Turnover | 0.03x | 0.08x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.15x | 0.13x | 0.08x | 0.78x | 0.20x | 0.53x | 1.18x | 1.58x |
| Asset Growth % | 207.18% | 21.15% | 51.38% | 12.72% | 113.58% | 55.2% | 333.73% | -54.25% | 26.04% | 1132.24% | -66.99% | 59.5% | 120.25% | 32.08% | - |
| Total Current Liabilities | 70.05M | 70.7M | 47.87M | 26.64M | 33.35M | 13.64M | 10.67M | 10.18M | 6.73M | 3.9M | 4.58M | 2.47M | 1.99M | 1.39M | 23.6M |
| Accounts Payable | 9.3M | 8.68M | 2.14M | 2.24M | 14.23M | 2.33M | 670K | 1.1M | 571K | 906K | 159K | 242K | 255K | 100K | 26.66K |
| Days Payables Outstanding | 1.97K | - | - | - | - | - | 8.64 | - | 6.85 | 16.85 | 22.78 | 35.73 | 28.7 | 14.61 | 3.2 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.98M | 2.29M | 0 | 0 | 1.1M | 80K | 697.06K | 22.59M |
| Deferred Revenue (Current) | 822K | 367K | 288K | 288K | 288K | 289K | 301K | 0 | 3.79M | 0 | 3.38M | 1.02M | 0 | 76.41K | 788.19K |
| Other Current Liabilities | 0 | 19.66M | 10.74M | 12.75M | 4.87M | 3.75M | 7.29M | 674K | 239K | 353K | 1.17M | 295K | 1.4M | 194.31K | 200K |
| Current Ratio | 14.46x | 12.65x | 15.43x | 18.26x | 12.73x | 14.68x | 12.14x | 2.92x | 9.71x | 13.31x | 0.93x | 4.75x | 3.41x | 1.48x | 0.07x |
| Quick Ratio | 14.46x | 12.65x | 15.43x | 18.26x | 12.93x | 14.68x | 12.14x | 2.92x | 9.71x | 13.31x | 0.91x | 4.68x | 3.32x | 1.22x | 0.06x |
| Cash Conversion Cycle | -1.61K | - | - | - | - | - | - | - | - | - | 43.71 | 48.54 | 83.37 | 121.54 | 116.19 |
| Total Non-Current Liabilities | 377.92M | 106.56M | 22.89M | 21.77M | 6.68M | 2.36M | 544K | 4.33M | 8.07M | 10.07M | 2.82M | 24K | 109K | 259.35K | 620.85K |
| Long-Term Debt | 242.46M | 49.94M | 20.58M | 20.2M | 4.64M | 0 | 0 | 4.33M | 8M | 9.92M | 2.82M | 0 | 0 | 0 | 42.05K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 520K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 135.46M | 22.37M | 2.02M | 989K | 1.17M | 688K | 544K | 0 | 66K | 152K | 0 | 24K | 109K | 259.35K | 578.8K |
| Total Liabilities | 447.97M | 177.25M | 70.76M | 48.4M | 40.03M | 15.99M | 11.22M | 14.51M | 14.8M | 13.97M | 4.58M | 2.49M | 2.1M | 1.65M | 24.22M |
| Total Debt | 243.27M | 50.69M | 21.09M | 21.05M | 5.26M | 1.04M | 455K | 8.3M | 10.3M | 9.92M | 1.04M | 1.1M | 80K | 697.06K | 22.63M |
| Net Debt | 70.41M | -161.69M | -78.5M | -81.78M | -150.32M | -41.26M | -45.44M | -16.54M | -22.31M | -37.52M | -2.3M | -9.73M | -5.04M | 487.72K | 22.52M |
| Debt / Equity | 0.42x | 0.07x | 0.03x | 0.05x | 0.01x | 0.01x | 0.00x | 0.53x | 0.20x | 0.26x | - | 0.11x | 0.01x | 0.34x | - |
| Debt / EBITDA | -0.52x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.15x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -15.75x | -68.24x | -87.62x | -127.71x | -266.23x | -26470.00x | -79.76x | -49.15x | -36.46x | -68.22x | -132.41x | -79.34x | -6.71x | -0.10x | -2.53x |
| Total Equity | 580.7M | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | -326K | 10.41M | 5.99M | 2.03M | -21.44M |
| Equity Growth % | 56.71% | 7.52% | 51.95% | 11.89% | 110.46% | 56.38% | 661.95% | -69.32% | 33.33% | 11912.88% | -103.13% | 73.76% | 195.63% | 109.45% | - |
| Book Value per Share | 5.12 | 8.52 | 9.89 | 9.88 | 12.31 | 15.75 | 33.75 | 7.54 | 26.02 | 30.02 | -0.45 | 19.30 | 39.84 | 10.77 | -115.23 |
| Total Shareholders' Equity | 580.7M | 722.17M | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | -326K | 10.41M | 5.99M | 2.03M | -21.44M |
| Common Stock | 1.14M | 1.02M | 810K | 540K | 414K | 239K | 42K | 23K | 308K | 226K | 7K | 106K | 38K | 27.91K | 0 |
| Retained Earnings | -1.67B | -1.34B | -995.86M | -725.91M | -488.17M | -358.3M | -278.89M | -168.17M | -126.3M | -93.59M | -30.64M | -17.97M | -6.64M | -25.89M | -21.44M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.2M | 447K | -10K | 338K | -390K | -157K | -8K | 0 | -3K | -2.83M | 0 | -739K | -555K | -411.05K | -262.74K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying VRDN stock.
As of 2025, Viridian Therapeutics, Inc. (VRDN) had total assets of $899.4M including $894.2M in current assets.
Viridian Therapeutics, Inc. (VRDN) carries total debt of $50.7M, offset by $874.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Viridian Therapeutics, Inc. (VRDN) has total shareholders' equity (book value) of $722.2M ($8.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Viridian Therapeutics, Inc. (VRDN) reported a current ratio of 12.65x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway versus Phase 3 funding
Metrics are mathematically derived from official filings.
Balance Sheet Expanding Through Equity Raises
According to reported quarterly figures, VRDN's total assets climbed from $585.7M in 2024Q2 to $1.0B in 2026Q3 while equity grew to $580.7M, a pattern that points to externally funded expansion rather than internally generated strength.
The rise in total assets appears driven largely by capital raised against an accumulated deficit that reached roughly -$1.7B, indicating the balance sheet is being sustained by financing rather than earnings. Equity remained the dominant funding source throughout the period, which suggests the trajectory is one of dependence on capital markets. Investors should monitor whether the asset base continues to grow faster than the burn rate, as this would signal the company is building durable cash coverage rather than simply deferring dilution.
Cash Buffer Thin Against Phase 3 Spend
As reported in financial statements, VRDN held $172.9M in cash at 2026Q3 against a current ratio of 14.46, a liquidity profile that looks strong on paper but may be inadequate relative to quarterly operating outflows of roughly $90M to $125M.
The high current ratio largely reflects the absence of meaningful current liabilities rather than a surplus of deployable cash, so the ratio overstates true flexibility. Cash on hand appears to cover only a limited number of quarters at recent burn levels, which may indicate that completing the THRIVE programs will require additional capital. This warrants close monitoring of the next financing event and its terms.
Minimal Leverage Keeps Balance Sheet Flexible
Based on EDBL's reported figures, VRDN's total debt of $243.3M at 2026Q3 against equity of $580.7M yields a debt-to-equity ratio of 0.42, a level that is modest but has risen sharply from 0.04 a year earlier.
The step-up in debt during 2026 changes the risk profile, as it introduces a fixed obligation into a company with negative operating cash flow. Leverage remains low in absolute terms, which preserves some flexibility, but the rapid increase suggests the company is now drawing on borrowing alongside equity. The durability of this structure depends on whether debt is used to bridge to a commercial launch or to extend a runway that would otherwise require dilutive equity.
Deferred Revenue Signals Milestone Timing
According to reported figures, VRDN's deferred revenue rose to $36.4M in 2026Q1 and $34.6M in 2025Q4 after sitting near $0.5M through 2025, a pattern that suggests upfront or milestone payments have been received but not yet recognized.
Deferred revenue of this size implies contractual performance obligations that will convert to revenue in future periods, lending some visibility to near-term reported income. However, it is not evidence of recurring demand and is consistent with the lumpy milestone pattern seen across recent quarters. Investors should treat the conversion of this balance as a timing item rather than a durable revenue base.
Accumulated Deficit Masks Equity Quality
Based on reported figures, VRDN's retained earnings of roughly -$1.7B against positive reported equity of $580.7M suggests that book equity reflects capital contributed rather than value created, and stock-based compensation of $30.4M in 2026Q2 adds ongoing dilution pressure.
The gap between accumulated losses and current equity indicates that prior shareholder capital has been consumed by operations, so headline book value may overstate the cushion available to absorb further losses. Recurring stock-based compensation at this scale may mean that a portion of the operating loss is non-cash, yet it still transfers economic value to employees through dilution. Investors should weigh book equity against fully diluted share count and the likelihood of future raises before drawing conclusions about balance sheet strength.